Unique ID issued by UMIN | UMIN000027876 |
---|---|
Receipt number | R000031942 |
Scientific Title | Clinical assessment of long-term glucose-lowering effects of DPP-4 inhibitor under different dietary habits in Japanese individual with type 2 diabetes |
Date of disclosure of the study information | 2017/06/22 |
Last modified on | 2017/06/22 20:35:33 |
Clinical assessment of long-term glucose-lowering effects of DPP-4 inhibitor under different dietary habits in Japanese individual with type 2 diabetes
DPP-4i and dietary habits
Clinical assessment of long-term glucose-lowering effects of DPP-4 inhibitor under different dietary habits in Japanese individual with type 2 diabetes
DPP-4i and dietary habits
Japan |
diabetes
Endocrinology and Metabolism |
Others
NO
To assess potential relationship between dietary contents, especially intakes of macro-nutrients and fats, and the long-term durability of DPP-4 inhibitor sitagliptin in Japanese individuals with type 2 diabetes
Others
To assess potential relationship between body-weight changes and the long-term durability of DPP-4 inhibitor sitagliptin in Japanese individuals with type 2 diabetes
Differences in intake of carbohydrates, proteins and fats as well as that of saturated fats, monounsaturated fats, and polyunsaturated fats between patients with HbA1c deteriorated 6 months after sitagliptin initiation [deltaHbA1c (12-6 mo) 0.4% or less] and those with HbA1c maintained [deotaHbA1c(12-6mo) above 0.4%]
Differences in bodyweight cahnges between patients with HbA1c deteriorated 6 months after sitagliptin initiation [deltaHbA1c (12-6 mo) 0.4% or less] and those with HbA1c maintained [deotaHbA1c(12-6mo) above 0.4%]
Observational
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Those initiated and continued DPP-4 inhibitor sitagliptin monotherapy for 12 months
2) those submitted at least one 3-day food record during 18 months after sitagliptin initiation
3) those received at least four measurements of HbA1c, creatinine and bodyweight during 12 months after sitagliptin initiation
1) Those initiated sitagliptin monotherapy in replacement of other anti-diabetic
2) Those received other anti-diabetic drugs during 0 - +12 months after sitagliptin initiation
3) Those received medications affecting HbA1c levels during 0 - +12 months after sitagliptin initiation
4) those had moderate/severe renal insufficiency (creatinine >1.5 mg/dL) at sitagliptin initiation
5) those had moderate/severe hepatic insufficiency (Child-Pugh B or above) at sitagliptin initiation
6) Those became pregnant during 0 - +12 months after sitagliptin initiation
7) Those received anti-cancer therapies during -12 - +24 months after sitagliptin initiation
100
1st name | |
Middle name | |
Last name | Daisuke Yabe |
Kansai Electric Power Medical Research Institute
Yutaka Seino Distinguished Center for Diabetes Center
1-5-6 Minatojimaminamimachi, Chuo-ku, Kobe 650-0047, Japan
078-303-6090
ydaisuke-kyoto@umin.ac.jp
1st name | |
Middle name | |
Last name | Daisuke Yabe |
Kansai Electric Power Medical Research Institute
Yutaka Seino Distinguished Center for Diabetes Center
1-5-6 Minatojimaminamimachi, Chuo-ku, Kobe 650-0047, Japan
078-303-6090
ydaisuke-kyoto@umin.ac.jp
Kansai Electric Power Medical Research Institute
Kansai Electric Power Medical Research Institute
Profit organization
NO
2017 | Year | 06 | Month | 22 | Day |
Unpublished
Completed
2017 | Year | 03 | Month | 31 | Day |
2017 | Year | 04 | Month | 01 | Day |
None
2017 | Year | 06 | Month | 22 | Day |
2017 | Year | 06 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031942
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |